Concepedia

Clinicopathological and prognostic significance of PD‐L1 in oral cancer: A preliminary retrospective immunohistochemistry study

Daniel Lenouvel, Miguel Ángel González‐Moles, Isabel Ruiz‐Ávila, C.E. Chamorro-Santos, Lucía González‐Ruiz, Isabel González‐Ruiz, Pablo Ramos‐García

Oral Diseases · 2020 · 43 citations · 41 references

DOI

Abstract

PD-L1 expression is more common in non-smokers and non-drinkers, and its presence in the adjacent non-tumour epithelium suggests it may be involved in early oncogenesis.

References

41

Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries

Freddie Bray, Jacques Ferlay, Isabelle Soerjomataram et al. · CA A Cancer Journal for Clinicians · 2018 · 86.6K citations · Full text

Nivolumab vs investigator’s choice in recurrent or metastatic squamous cell carcinoma of the head and neck: 2-year long-term survival update of CheckMate 141 with analyses by tumor PD-L1 expression

Robert L. Ferris, George R. Blumenschein, Jérôme Fayette et al. · Oral Oncology · 2018 · 776 citations · Full text

, , +9

The head and neck cancer immune landscape and its immunotherapeutic implications

Rajarsi Mandal, Yasin Şenbabaoğlu, Alexis Desrichard et al. · JCI Insight · 2016 · 773 citations · Full text

The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of squamous cell carcinoma of the head and neck (HNSCC)

Ezra E.W. Cohen, R. Bryan Bell, Carlo Bifulco et al. · Journal for ImmunoTherapy of Cancer · 2019 · 712 citations · Full text

, , +24

Efficacy and safety of pembrolizumab in recurrent/metastatic head and neck squamous cell carcinoma: pooled analyses after long-term follow-up in KEYNOTE-012

Ranee Mehra, Tanguy Y. Seiwert, Shilpa Gupta et al. · British Journal of Cancer · 2018 · 443 citations · Full text